Acumen Pharmaceuticals, Inc. Common Stock
ABOSAcumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease. The company emphasizes innovative approaches to address the underlying causes of cognitive decline, aiming to improve patient outcomes through its research and development efforts in the neurodegeneration space.
Company News
Acumen Pharmaceuticals reported Q1 2026 financial results with cash reserves of $128.4 million. The company expects topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026, and plans to file an IND for its lead EBD program candidate in mid-2027. R&D expenses decreased to $16.5 million...
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The company is advancing its lead candidate sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers, in its Phase 2 ALTITUDE-AD trial for early symptomatic Al...
Acumen Pharmaceuticals announced it will report first quarter 2026 financial results on May 12, 2026, with a conference call and webcast at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, with topline results from...
Acumen Pharmaceuticals announced it will report Q4 and year-end 2025 financial results on March 26, 2026, with a conference call at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials.
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 tri...
